Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutation in BRAF V600E: A Poor Prognostic Marker in Stage III Colon Cancers With Deficient MMR?

JAMA oncology - 1 Sept 2017

Emambux Sheik, Mouillet Guillaume, Tougeron David

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mutation
Share to Colonic Neoplasms
Share to DNA Mismatch Repair
Share to Neoplasm Recurrence, Local

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Prognosis

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Share to Randomized Controlled Trials as Topic

Source

Identifiers

PMID: 28617898
DOI: 10.1001/jamaoncol.2017.0262

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutation in BRAF V600E: A Poor Prognostic Marker in Stage III Colon Cancers With Deficient MMR?PMID 28617898Read ↗

The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patientsSemantic proximity Read ↗

Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147.Semantic proximity Read ↗

Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer.Semantic proximity Read ↗

Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.Semantic proximity Read ↗

Prognostic and clinicopathologic significance of BRAF mutation in colon cancer by MSI status and stage: A large cohort analysis.Semantic proximity Read ↗

Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.Semantic proximity Read ↗

Prognostic value of Lynch syndrome, BRAFV600E , and RAS mutational status in dMMR/MSI-H metastatic colorectal cancer in a pooled analysis of Dutch and French cohorts.Semantic proximity Read ↗

Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.Semantic proximity Read ↗

Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation.Semantic proximity Read ↗

BRAF mutation in colorectal cancer: An updateSemantic proximity Read ↗

BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysis.Semantic proximity Read ↗

Age-related incidence of mismatch repair deficiency (dMMR) and its prognostic role in BRAF-mutant colorectal cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.